CONTACT: Sam Shull media@extheramedical.com
Proven treatment for critically ill patients is now available to federal organizations
MARTINEZ, Calif. – ExThera Medical Corporation has been awarded a 5-year U.S. Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) contract, which allows ExThera to pursue contracts with federal healthcare organizations including the U.S. Department of Veteran Affairs, U.S. Federal Prison System, Indian Reservations, and the Department of Defense. The contract grants streamlined access to the company’s Seraph® 100 MicroBind® Affinity Blood Filter. Military and VA clinicians have been enthusiastic users of Seraph 100 for the treatment of COVID-19. News articles featuring Seraph 100 have been published by the Uniformed Services University and VA News.
“ExThera is proud to be contracted by the Federal Supply Schedule, working closely with federal agencies to expand access to the Seraph 100. We have a growing body of evidence demonstrating lifesaving treatment for critically ill COVID-19 patients who often suffer from other ‘superinfections’ caused by bacteria and fungi,” said Robert Ward, Chairman, President and founder of ExThera Medical.
To date, the Seraph 100 has received both European Union CE Mark under the Medical Device Directive and Emergency Use Authorization (EUA) to treat COVID-19 in the United States and Canada.
“ExThera is committed to pursuing wider domestic and global access to its Seraph 100, to reach more patients, and provide treatment options to those who need them most. The FSS contract is a major step in achieving that goal for the United States,” said Sam Shull, Chief Commercial Officer at ExThera Medical.
Recent studies have demonstrated that the Seraph 100 quickly lowers the concentration of bacteria, viruses, and fungi, and most notably in critically ill patients suffering from SARS-CoV-2. In addition, Seraph 100 has been shown to significantly reduce the bloodstream concentration of many drug-susceptible and drug-resistant pathogens, providing a long-awaited therapy that addresses the severe problem of drug-resistance along with new and future microbial threats like variants of the SARS-CoV-2 virus.
###
About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 MicroBind® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph can be used in hospitals, clinics, on battlefields and in other austere environments to address nosocomial and community-acquired infections as well as those caused by battlefield wounds, pandemics, and biological warfare agents. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis, COVID-19, and many other severe bloodstream infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US, the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. The Seraph® 100 attained CE Mark and is commercially available in the EU under a broad Indication For Use. The Seraph 100 has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.
For more information, visit the company’s website at www.extheramedical.com.
About Seraph 100 and the ONCOBind Procedure
As a patient’s blood flows through the Seraph 100 filter, it passes through a bed of small beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s proprietary adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind circulating tumor cells, bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.
For more news stories on the Seraph 100 and the ONCOBind Procedure, click here.
Disclaimer
All information contained in this news release derives from plausible, reliable sources which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release. Results from case studies (reviews) may not be predictive of future results.
MM0006 Rev B